When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Recent Videos in Chronic Lymphocytic Leukemia (CLL)
Chromosomes, FISH, and Why Cytogenetics Matter in CLL This episode explains how chromosome analysis helps predict prognosis in chronic lymphocytic leukemia, starting with the basics of how chromosomes…
Join us for an informative webinar featuring Dr. Jennifer Woyach as she provides an overview of the current CLL treatment landscape and the many options available to patients…
Previous attempts to treat Christine’s Chronic Lymphocytic Leukemia (CLL) had failed. She participated in a clinical trial and subsequently went through a CAR T-cell transplant at the NCI-designated…
Profiling the metabolites produced by cells in Richter transformation could help researchers develop new targeted therapies in the future. Dr. Prajish Iyer from City of Hope National Comprehensive…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
